A randomized phase 2 study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: SWOG S1613.

Autor: Raghav, Kanwal Pratap Singh, Guthrie, Katherine A, Kopetz, Scott, Tan, Benjamin R., Denlinger, Crystal S., Fakih, Marwan, Overman, Michael J., Dasari, Arvind, Corum, Larry R., Hicks, Lee G., Patel, Mital, Esparaz, Benjamin T, Kazmi, Syed Mohammad Ali, Alluri, Nitya, Colby, Sarah, Gholami, Sepideh, Gold, Philip Jordan, Chiorean, E. Gabriela, Hochster, Howard S., Philip, Philip Agop
Zdroj: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p140-140, 1p
Databáze: Supplemental Index